These are celebrities’ faces reimagined 👩💻
These are celebrities’ faces reimagined 👩💻
The "Ireland Plant Protein Business and Investment Opportunities (2018-2027) Databook Series - Market Size and Forecast Across 50+ Segments - by Product Categories, Ingredients, Distribution Channels, Functional Type, Price Point, and Consumer Demographics - Updated in Q3, 2020" report has been added to ResearchAndMarkets.com's offering.
The best Cyber Monday mattress deals for 2020, including the top Purple, Tempur-Pedic, Leesa and Casper sales
Jofra Archer is being considered for a rest for the rearranged two-match series.
FTSE 100 heads for best month on record after Covid vaccine hopesGlobal markets have soared since pharmaceutical firms reported promising trial results * Coronavirus – latest updates * See all our coronavirus coverage
The six-episode HBO limited series wrapped on Sunday, revealing who killed Elena Alves
EasyJet said it will give passengers access to cheaper and easier testing options for as low as £75 via partnerships with two firms.
A British parliamentary committee has called on the pensions regulator to fight for those workers at Philip Green's Arcadia Group which is battling to secure its future during the pandemic. Stephen Timms, the head of the work and pensions committee, has called for support for the Arcadia pension scheme members. "There is unquestionably a moral case for the Green family to do the right thing and guarantee Arcadia's hardworking staff what is rightfully theirs, whatever happens this Christmas," Timms said in a statement.
Billionaire Issa brothers make bid for struggling Caffè NeroPair behind petrol station company EG Group want to take over coffee shop chain * Coronavirus – latest updates * See all our coronavirus coverage
Compatriot Laia Sanz, a 13-times women's trial motorcycle world champion, will be his team mate. Sanz has reached the finish 10 times in the Dakar Rally on two wheels with a best result of ninth. Sainz, 58, is the father of Ferrari-bound McLaren Formula One driver Carlos Sainz Jr, who will also be a shareholder in the all-Spanish ACCIONA Sainz XE team.
The 29-year-old unionist law lecturer was shot dead by the IRA in 1983.
David Chang won $1 million for his charity, the Southern Smoke Foundation
"I can't believe it got physical," the "Orange Is the New Black" actor said on Instagram soon after the incident took place.
Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s diseaseBETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM. Under the terms of the collaboration, UMSOM will investigate Gain’s STAR candidates in macrophage and neuronal models of nGD and GBA-associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gain’s STAR candidates by studying their effect on GCase, including GCase’s enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated. “We are exceedingly proud to be advancing our work in nGD and Parkinson’s in close collaboration with the University of Maryland School of Medicine,” said Eric Richman, Chief Executive Officer at Gain. “The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gain’s STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.” Dr. Feldman added, “Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA-associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gain’s initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gain’s team to further advance its program to treat these diseases.” Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021. About Gain Therapeutics, Inc.Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For more information, visit https://www.gaintherapeutics.com/. Forward-Looking StatementsAny statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding Gain Therapeutics, Inc. (Gain) expected use of the proceeds from the Series B financing round; the market opportunity for Gain’s product candidates; and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Gain’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Gain Therapeutics Investor Contact:Daniel FerryLifeSci Advisors+1 email@example.com Gain Therapeutics Media Contact:Cait Williamson, Ph.D.LifeSci Communications+1 firstname.lastname@example.org
The "European Wind Turbine Market Outlook Update Q3 2020" report has been added to ResearchAndMarkets.com's offering.
Here's how to see an incredible spectacle that hasn't happened in 800 years.
Neera Tanden has been tapped to head the Office of Management and Budget for President-elect Joe Biden, setting her up to take on one of the most daunting tasks in Washington in the coming years.
Liverpool defender Andy Robertson has become the third player from the Premier League champions to publicly question whether the use of VAR technology should continue in the game. Captain Jordan Henderson and midfielder James Milner came out with broad-ranging criticisms of the video review system after Saturday's 1-1 draw at Brighton & Hove Albion. Milner said he was "falling out of love with the game in its current state".
"It was a spur of the moment decision made with the misguided view that we were coming out of lockdown and this would be OK," she said.
TV presenter Hayley Matthews, who hosted the party’s virtual conference, has previously expressed support for conspiracy theories.
A new inquest into the death of Ella Kissi-Debrah is probing whether illegal pollution in the London Borough of Lewisham caused a fatal asthma attack.